Alvotech Reveals Encouraging Preliminary Findings from Drug Behavior Analysis of AVT03, a Potential Equivalent to Prolia® and Xgeva®.

Oricell has received the green light from the FDA for its investigational new drug (IND) application for OriCAR-017, an innovative CAR-T therapy aimed at GPRC5D.

Sarepta Therapeutics Reveals Encouraging Results from Segment B in the MOMENTUM Phase 2 Trial for SRP-5051, Targeting Exon 51 Skip-Amenable Duchenne Muscular Dystrophy Cases.

Takeda has disclosed that GAMMAGARD LIQUID®, their intravenous immunoglobulin treatment, has received authorization from the U.S. Food and Drug Administration.

Alligator Bioscience Reveals Encouraging Phase 2 Outcomes from OPTIMIZE-1 Study, Succeeding in Main Goal and Showing Significant Survival Advantages for Initial Treatment of Pancreatic Cancer.

Vidac Pharma shares encouraging early results from a Phase 2a trial for a rare skin cancer, cutaneous T-cell lymphoma, using its primary drug candidate, VDA-1102.

Asieris Debuts Preliminary Results from Study on APL-1202 Pill Paired with Immune Checkpoint Blocker Tislelizumab for Pre-Surgical Care in Advanced Urinary Bladder Tumors at ASCO-GU 2024 Event.

Celltrion USA has finalized its application for a biosimilar approval, targeting CT-P47, a counterpart to the drug ACTEMRA® (tocilizumab).

European Commission Sanctions Takeda's HYQVIA® for Ongoing Treatment in Chronic Inflammatory Demyelinating Polyneuropathy Cases.

U.S. authorities expedite assessment of ENHERTU® for individuals suffering from advanced solid cancers with HER2-positive status.

Nivolumab plus hyaluronidase administered beneath the skin is comparably effective to Opdivo given intravenously for advanced or metastatic clear cell kidney cancer as suggested by study CheckMate -67T.

On Jan 26, Pfizer and Astellas Pharma announced that the European Medicines Agency (EMA) has accepted to review a Type II variation application for the combined use of PADCEV® and KEYTRUDA®.